Member of the Association of American Physicians
Eric P. Winer mainly investigates Internal medicine, Breast cancer, Oncology, Cancer and Chemotherapy. His Internal medicine research includes elements of Gynecology and Surgery. His research integrates issues of Chemotherapy regimen, Radiation therapy and Adjuvant therapy in his study of Breast cancer.
His Oncology research incorporates elements of Clinical trial, Trastuzumab, Randomized controlled trial, Paclitaxel and Mastectomy. His Cancer study combines topics from a wide range of disciplines, such as Germline mutation and Pathology. His study looks at the relationship between Chemotherapy and fields such as Anthracycline, as well as how they intersect with chemical problems.
Eric P. Winer mainly focuses on Internal medicine, Breast cancer, Oncology, Cancer and Metastatic breast cancer. His studies examine the connections between Internal medicine and genetics, as well as such issues in Surgery, with regards to Cohort. His study in Breast cancer is interdisciplinary in nature, drawing from both Stage, Gynecology and Disease.
His Oncology research integrates issues from Adjuvant therapy, Regimen, Paclitaxel and Phases of clinical research. Eric P. Winer combines subjects such as Adverse effect, Family medicine and Pathology with his study of Cancer. His Metastatic breast cancer research is multidisciplinary, relying on both Cancer research, Tolerability, Letrozole, Clinical endpoint and Fulvestrant.
His primary scientific interests are in Internal medicine, Breast cancer, Oncology, Metastatic breast cancer and Cancer. His work carried out in the field of Breast cancer brings together such families of science as Stage, Adverse effect, Cancer research and Clinical trial. The study incorporates disciplines such as Pembrolizumab, Hormone receptor, Trastuzumab and Chemotherapy in addition to Oncology.
His work deals with themes such as Regimen and Capecitabine, which intersect with Trastuzumab. His Metastatic breast cancer course of study focuses on PARP inhibitor and Reversion and Germline. His Cancer study incorporates themes from Bevacizumab, Epidemiology and Disease.
Breast cancer, Internal medicine, Oncology, Metastatic breast cancer and Cancer are his primary areas of study. The concepts of his Breast cancer study are interwoven with issues in Adverse effect, Capecitabine, Cohort and Immunotherapy. Eric P. Winer works mostly in the field of Cohort, limiting it down to concerns involving Disease and, occasionally, Radiation therapy.
Eric P. Winer interconnects Clinical trial, Pertuzumab, Trastuzumab, Chemotherapy and Randomized controlled trial in the investigation of issues within Oncology. The various areas that Eric P. Winer examines in his Metastatic breast cancer study include Exome sequencing, Cancer research, PARP inhibitor, Germline and Letrozole. His Cancer study combines topics in areas such as Drug, Drug resistance and PTEN.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
A Goldhirsch;E P Winer;A S Coates;R D Gelber.
Annals of Oncology (2013)
American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer
Gary H. Lyman;Armando E. Giuliano;Mark R. Somerfield;Al B. Benson.
Journal of Clinical Oncology (2005)
Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741
Marc L. Citron;Donald A. Berry;Constance Cirrincione;Clifford Hudis.
Journal of Clinical Oncology (2003)
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
Kathy S Albain;William E Barlow;Steven Shak;Gabriel N Hortobagyi.
Lancet Oncology (2010)
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
A. S. Coates;E. P. Winer;A. Goldhirsch;R. D. Gelber.
Annals of Oncology (2015)
American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004
Eric P. Winer;Clifford Hudis;Harold J. Burstein;Antonio C. Wolff.
Journal of Clinical Oncology (2002)
Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study
Philip W. Kantoff;Susan Halabi;Mark Conaway;Joel Picus.
Journal of Clinical Oncology (1999)
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
Daniel P. Silver;Andrea L. Richardson;Aron C. Eklund;Zhigang C. Wang.
Journal of Clinical Oncology (2010)
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Gabriel N. Hortobagyi;Salomon M. Stemmer;Howard A. Burris;Yoon-Sim Yap.
The New England Journal of Medicine (2016)
American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer
Harold J. Burstein;Ann Alexis Prestrud;Jerome Seidenfeld;Holly Anderson.
Journal of Clinical Oncology (2010)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: